Updated:
New York Genome Center
The New York Genome Center is a nonprofit genomics consortium founded in 2010, operating one of North America's largest sequencing facilities in Manhattan.
New York Genome Center
The New York Genome Center was founded in 2010 as a collaborative nonprofit bringing together 11 founding academic medical centers including Columbia University, Rockefeller University, and Cold Spring Harbor Laboratory to pool genomic sequencing capacity and expertise. Tom Maniatis, a pioneering molecular biologist, served as the founding board chair and helped shape its mission to accelerate genomic medicine through shared infrastructure. The center operates a large-scale sequencing facility in Manhattan capable of processing over 50,000 human genomes per year, offering services across whole-genome sequencing, exome sequencing, RNA sequencing, and single-cell genomics. Its work spans cancer genomics, rare disease diagnostics, and population health — notably collaborating with the New York City Department of Health on pathogen surveillance. The facility processes samples for both academic and commercial clients, with confirmed projects including the Human Cell Atlas and clinical trials for multiple pharmaceutical partners (per the center's annual reports and news releases). The center currently employs over 200 scientists and staff across its genomics, computational biology, and informatics groups. A major operational milestone came when it expanded its CLIA-certified clinical lab in 2023, increasing diagnostic capacity for rare genetic disorders in underserved populations (per news releases from the center, 2023). Adjacent philanthropic structures include the New York Genome Center Foundation, a separate charitable entity supporting community outreach and education. The New York Genome Center is structurally distinct from typical genomic research organizations in two ways: it operates as a nonprofit consortium owned by its member institutions rather than a standalone institute or company, and it combines a clinical diagnostic lab with a large-scale research sequencing facility under one roof. This hybrid model allows it to bridge academic discovery and clinical application more directly than most genomics centers.
General information
Firm type
other
Year founded
2010
AUM
Undisclosed
Location
Region
North America
Country
United States
City
New York
Corporate office
New York, NY, United States
Principals
Tom Maniatis
Founding Board Chair
David Goldstein
Director
Sector focus
Frequently asked questions
What is the New York Genome Center's primary mission?
The New York Genome Center is a nonprofit consortium focused on accelerating genomic medicine through shared infrastructure and collaborative research. Its mission is to apply genomic science to improve human health, with a particular emphasis on cancer, rare diseases, and population health (per the center's public mission statement).
How does the New York Genome Center generate revenue?
The center generates revenue through fee-for-service sequencing and analysis for academic, pharmaceutical, and clinical clients. It also receives philanthropic donations, grant funding from sources like the NIH, and membership dues from its academic medical center members.
Does the New York Genome Center conduct its own research, or is it exclusively a service provider?
The center both operates a service-oriented sequencing facility and conducts its own independent research. Its scientific teams pursue projects in computational genomics, cancer biology, and neurogenomics, often in collaboration with member institutions (per publications and center webpages).
Which diseases or conditions does the New York Genome Center focus on?
The center's research and clinical work concentrates heavily on cancer genomics, rare genetic disorders, and neurodegenerative diseases. It also participates in large-scale population studies and infectious disease surveillance, as seen with its COVID-19 genomic monitoring for New York City (per public health partnerships).
How does the New York Genome Center relate to pharmaceutical companies?
The center works with pharmaceutical partners on clinical trials and biomarker discovery, providing sequencing and analysis services. It does not typically develop therapies itself but supports drug development through genomic data generation and interpretation (per the center's partnership descriptions).
Is the New York Genome Center affiliated with any specific university?
No, it is an independent nonprofit consortium jointly governed by 11 founding academic medical centers, including Columbia University, Weill Cornell Medicine, Rockefeller University, and Cold Spring Harbor Laboratory. It does not belong to a single institution (per the center's governance structure).
What is the relationship between the New York Genome Center and the New York Genome Center Foundation?
The New York Genome Center Foundation is a separate nonprofit charitable entity that supports community engagement, education, and philanthropic fundraising for the Center's programs. It is legally distinct from the research and clinical operations (per IRS filings).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: